| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Reproductive System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Reproductive System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Reproductive System |
Recent Updates
Recently added Catalysts
Hemab Therapeutics Holdings, Inc.$29.97
-1.03 (-3.32%)
D 37Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.21 B
EPS
-
P/E Ratio
-
Value Trade
5.61 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
19.46 M
Operating CF
-21.58 M
Total Assets
175.26 M
Total Liabilities
13.71 M
Equity
-198.62 M
D/E Ratio
12,345
-8.71 %
Week
-16.13 %
1 Month
-16.13 %
3 Month
-16.13 %
6 Month
-16.13 %
5 Year
-16.13 %
All Time
Cash Data
Cash Position
163.53 M
Monthly Burn
7.20 M
Runway
21.3 mo
Burn Trend
SEC Filing
May 21, 2026
Overview
Volume
618.12 K
52 Week Range
23.00 - 32
% held by Insiders
28.79 %
% held by Institutions
32.9 %
Enterprise Value
1.41 B
Total Shares
39.25 M
Short %
4.07 %
Float Shares
15.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hemab Therapeutics Holdings, Inc.
12Total events
8Upcoming
2Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 8
Jul 11, 2026
T2Oral Presentation
HMB-003, a long-acting peptide plasmin inhibitor, potently inhibits fibrinolysis and localizes with fibrin in a human whole blood microfluidic flow model
Jul 12, 2026
T2Oral Presentation
First-in-human investigation of HMB-002: a subcutaneous antibody for prophylactic management of Von Willebrand disease
Jul 12, 2026
T3Poster Presentation
Optimization of the Halo Fluorescence Fibrinolysis Assay: How Plasma Overlay and Timing Influence Antifibrinolytic Assessment
Jul 14, 2026
T2Oral Presentation
Sutacimig Prophylaxis in Glanzmann Thrombasthenia: Results from a Phase 2 Long-Term Extension
Jul 14, 2026
T3Poster Presentation
Substantial Bleeding Burden and Limited Prophylaxis Use in Glanzmann Thrombasthenia: Prospective Real-World Data from ATHN Transcends
Event history 4
Q3 2026
◆Trial InitiationSutacimigTrial
Phase 3 initiation planned for sutacimig in GT
Glanzmann thrombastheniasource ↗
Q3 2026
TBD
▲Breakthrough Therapy DesignationSutacimigDesignation
FDA Breakthrough Therapy Designation for sutacimig in GT
Glanzmann thrombastheniasource ↗
TBD
▲EMA PrimeSutacimigEx-US Regulatory
EMA PRIME designation for sutacimig in GT
Glanzmann thrombastheniasource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $245M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 51%
Micro Cap (rank 445 of 906)
Percentile RankHemab Therapeutics Holdings, Inc. faces pipeline headwinds (37/100), with $738M risk-adjusted pipeline value, led by Sutacimig in Congenital Factor VII Deficiency (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sutacimig Small molecule | Congenital Factor VII Deficiency | Phase 2 | NCT07347249 | 60% | $657M | RECRUITING | 18 | AVERAGE | D (29) | Jul 1, 2026 | - | LOW May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HMB-002 | Von Willebrand disease | — | 2026-06-26 | elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels Read More | Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress Read More | |
HMB-002 | Von Willebrand disease | — | 2026-06-26 | elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels Read More | Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress Read More | |
HMB-002 | Von Willebrand disease | — | 2026-06-26 | elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels Read More | Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COAG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COAG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COAGHemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
Hemab Therapeutics announced significant advancements in its blood coagulation programs, including promising first-in-human data for HMB-002 in Von Willebrand disease and the introduction of HMB-003, a new peptide plasmin inhibitor. The company plans to present nine studies at the ISTH 2026 Congress, showcasing its commitment to addressing critical gaps in coagulation disorder treatments. Sutacimig has also received FDA Breakthrough Therapy designation, with a Phase 3 trial expected to begin in the second half of 2026.
Read more →COAGHemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, where its management team will present and hold investor meetings. The event is scheduled for June 4, 2026, in New York, NY. Hemab is focused on developing therapies for blood coagulation disorders, including treatments for Glanzmann thrombasthenia and Von Willebrand Disease.
Read more →COAGHemab Therapeutics Reports First Quarter 2026 Financial Results Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for s
Hemab Therapeutics has reported its first quarter financial results for 2026, highlighting the successful completion of an initial public offering that raised $346.7 million and secured a listing on Nasdaq. The company received Breakthrough Therapy Designation for sutacimig, a bispecific antibody for Glanzmann thrombasthenia. Despite these advancements, Hemab reported a net loss of $22.687 million in the quarter, with a decrease in cash reserves compared to the previous quarter.
Read more →COAGHemab Therapeutics Announces Pricing of Upsized Initial Public Offering
Hemab Therapeutics Holdings, Inc. has announced the pricing of its initial public offering, offering 16,750,000 shares at $18.00 each. The IPO is expected to generate around $301.5 million in gross proceeds. Trading is set to begin on the Nasdaq Global Select Market under the ticker 'COAG' on May 1, 2026, with the offering closing around May 4, 2026.
Read more →Competitive Position
How COAG ranks across every disease it competes inCompetitive Position is a premium feature
See how COAG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial